{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T13:11:44Z","timestamp":1788873104682,"version":"build-2803163510"},"reference-count":63,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100024848","name":"IAS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024848","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007936","name":"International AIDS Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007936","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Hong Kong Jockey Club Global Health Institute"},{"name":"Hong Kong Special Administrative Region, China"},{"DOI":"10.13039\/100014305","name":"HIV Research Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014305","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Dolutegravir (DTG)-based antiretroviral therapy has been widely adopted across sub-Saharan Africa, yet resistance pathways in non-B HIV-1 subtypes remain poorly defined. As lenacapavir (LEN), a long-acting capsid inhibitor, is introduced for prevention and treatment, characterizing baseline capsid variation alongside emerging integrase resistance is increasingly important. Whether DTG resistance pathways coexist with known capsid resistance mutations in West African epidemics remains poorly described.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed deep sequencing of 87 HIV-1 samples from adults (n\u200a=\u200a47) and paediatric participants (n\u200a=\u200a40) failing DTG-based antiretroviral therapy in Nigeria. Resistance mutations were interpreted using Stanford HIVdb and IAS-USA criteria, with resistance estimates based on gene- or drug-panel-specific denominators. Low-frequency variants were assessed at 2%, 5%, 10% and 20% read-frequency thresholds. Capsid mutations associated with LEN resistance were characterized, structurally mapped and compared to global sequence data. HIV-1 subtype and recombinant forms were assigned using COMET HIV-1 v2.4.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At consensus, predicted resistance to \u22651 integrase strand transfer inhibitor (INSTI) was detected in 13\/50 integrase-genotypable participants (26.0%; 95% CI 15.9%\u201339.6%), including 5\/50 with a major INSTI resistance mutation. Reduced predicted susceptibility specifically to DTG was present in 6\/50 (12.0%; 95% CI 5.6%\u201323.8%). G118R was detected in 4\/50 participants at consensus, while Q148H\/K\/R and N155H were absent. In exploratory deep-sequencing analysis, G118R was detected in 8\/47 participants with sufficient codon-level coverage at the \u226520% read-frequency threshold. No known primary LEN resistance mutation was detected among 33 participants with complete coverage of all six primary resistance positions (0\/33; 95% CI 0%\u201310.4%); T107A, a polymorphic capsid substitution of uncertain effect on LEN susceptibility, was detected in in 3\/33 individuals where sequence could be evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings demonstrate DTG resistance in both adult and paediatric participants with virological failure with G118R emerging as a prominent resistance pathway. No known primary LEN resistance mutation was detected in the assessable capsid sequences, although phenotypic susceptibility and clinical outcomes were not evaluated. These findings support continued surveillance of integrase and capsid resistance as long-acting antiretroviral strategies expand.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkag300","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T11:33:40Z","timestamp":1787052820000},"source":"Crossref","is-referenced-by-count":0,"title":["HIV-1 integrase inhibitor resistance in viraemic-treated individuals and baseline capsid diversity relevant to future lenacapavir therapy"],"prefix":"10.1093","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9703-8264","authenticated-orcid":false,"given":"Adam","family":"Abdullahi","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Cambridge, Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID) , Cambridge ,","place":["UK"]},{"name":"International Research Centre of Excellence, Institute of Human Virology , Abuja ,","place":["Nigeria"]},{"name":"Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health , Boston, MA ,","place":["USA"]},{"name":"Hong Kong Jockey Club Global Health Institute , Hong Kong, SAR ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Osawe","sequence":"additional","affiliation":[{"name":"International Research Centre of Excellence, Institute of Human Virology , Abuja ,","place":["Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruna","family":"Wisso","sequence":"additional","affiliation":[{"name":"International Research Centre of Excellence, Institute of Human Virology , Abuja ,","place":["Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Edun","sequence":"additional","affiliation":[{"name":"International Research Centre of Excellence, Institute of Human Virology , Abuja ,","place":["Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Adebisi","sequence":"additional","affiliation":[{"name":"International Research Centre of Excellence, Institute of Human Virology , Abuja ,","place":["Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Arachie","sequence":"additional","affiliation":[{"name":"International Research Centre of Excellence, Institute of Human Virology , Abuja ,","place":["Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chinedu","family":"Ude","sequence":"additional","affiliation":[{"name":"International Research Centre of Excellence, Institute of Human Virology , Abuja ,","place":["Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Onyemata","sequence":"additional","affiliation":[{"name":"International Research Centre of Excellence, Institute of Human Virology , Abuja ,","place":["Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suleiman Yusuf","family":"Alhaji","sequence":"additional","affiliation":[{"name":"Molecular Genetics & Infectious Diseases Research Laboratory, Abubakar Tafawa Balewa University Teaching Hospital , Bauchi 740101 ,","place":["Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuf","family":"Bara Jibrin","sequence":"additional","affiliation":[{"name":"Department of Medicine, Abubakar Tafawa Balewa University Teaching Hospital , Bauchi 740272 ,","place":["Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alash\u2019le","family":"Abimiku","sequence":"additional","affiliation":[{"name":"International Research Centre of Excellence, Institute of Human Virology , Abuja ,","place":["Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven A","family":"Kemp","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Cambridge, Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID) , Cambridge ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravindra K","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Cambridge, Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID) , Cambridge ,","place":["UK"]},{"name":"Hong Kong Jockey Club Global Health Institute , Hong Kong, SAR ,","place":["China"]},{"name":"Africa Health Research Institute , Durban ,","place":["South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"key":"2026090808571937300_dkag300-B1","author":"UNAIDS"},{"key":"2026090808571937300_dkag300-B2","volume-title":"Update of Recommendations on First- and Second-Line Antiretroviral Regimens","author":"World Health Organization"},{"key":"2026090808571937300_dkag300-B3","volume-title":"National Guidelines for HIV Prevention, Treatment and Care. Abuja: Federal Ministry of Health; 2020. (NASCP\/FMOH, Abuja, Nigeria, 2020)","author":"Federal Ministry of Health, Nigeria","year":"2020"},{"key":"2026090808571937300_dkag300-B4","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/S1473-3099(17)30702-8","article-title":"HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis","volume":"18","author":"Gupta","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2026090808571937300_dkag300-B5","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S1473-3099(15)00536-8","article-title":"Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study","volume":"16","author":"Gregson","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2026090808571937300_dkag300-B6","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.1093\/jac\/dkz264","article-title":"An apparent paradox: resistance mutations in HIV-1 DNA predict improved virological responses to antiretroviral therapy","volume":"74","author":"Geretti","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2026090808571937300_dkag300-B7","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1093\/jac\/dkad386","article-title":"A detailed characterization of drug resistance during darunavir\/ritonavir monotherapy highlights a high barrier to the emergence of resistance mutations in protease but identifies alternative pathways of resistance","volume":"79","author":"Abdullahi","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"2026090808571937300_dkag300-B8","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1093\/cid\/ciad390","article-title":"Two-year outcomes of treatment-experienced adults after programmatic transitioning to dolutegravir: longitudinal data from the VICONEL human immunodeficiency virus cohort in Lesotho","volume":"77","author":"Tschumi","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2026090808571937300_dkag300-B9","doi-asserted-by":"publisher","first-page":"40858","DOI":"10.1074\/jbc.R112.397760","article-title":"Retroviral integrase proteins and HIV-1 DNA integration","volume":"287","author":"Krishnan","year":"2012","journal-title":"J Biol Chem"},{"key":"2026090808571937300_dkag300-B10","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12977-017-0360-7","article-title":"HIV drug resistance against strand transfer integrase inhibitors","volume":"14","author":"Anstett","year":"2017","journal-title":"Retrovirology"},{"key":"2026090808571937300_dkag300-B11","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jgar.2019.07.015","article-title":"Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors","volume":"20","author":"Scutari","year":"2020","journal-title":"J Glob Antimicrob Resist"},{"key":"2026090808571937300_dkag300-B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jve.2025.100608","article-title":"Prevalence of acquired resistance to HIV integrase strand transfer inhibitors (INSTIs) in clinical samples from treatment-experienced patients in Chile, 2012\u20132023","volume":"11","author":"Ferrer","year":"2025","journal-title":"J Virus Erad"},{"key":"2026090808571937300_dkag300-B13","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1093\/jac\/dkz417","article-title":"Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistance","volume":"75","author":"Tzou","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2026090808571937300_dkag300-B14","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1093\/jac\/dkad195","article-title":"Limited emergence of resistance to integrase strand transfer inhibitors (INSTIs) in ART-experienced participants failing dolutegravir-based antiretroviral therapy: a cross-sectional analysis of a northeast Nigerian cohort","volume":"78","author":"Abdullahi","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"2026090808571937300_dkag300-B15","doi-asserted-by":"publisher","first-page":"e1242","DOI":"10.1093\/cid\/ciag161","article-title":"Patterns of HIV-1 viral load suppression and drug resistance during the dolutegravir transition: a population-based longitudinal study","volume":"82","author":"Martin","year":"2026","journal-title":"Clin Infect Dis"},{"key":"2026090808571937300_dkag300-B16","doi-asserted-by":"publisher","first-page":"S127","DOI":"10.1097\/QAD.0000000000003082","article-title":"Adherence, resistance, and viral suppression on dolutegravir in sub-Saharan Africa: implications for the TLD era","volume":"35","author":"McCluskey","year":"2021","journal-title":"AIDS"},{"key":"2026090808571937300_dkag300-B17","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1056\/NEJMoa2407001","article-title":"Twice-yearly lenacapavir or daily F\/TAF for HIV prevention in cisgender women","volume":"391","author":"Linda-Gail","year":"2024","journal-title":"N Engl J Med"},{"key":"2026090808571937300_dkag300-B18","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/s41586-020-2443-1","article-title":"Clinical targeting of HIV capsid protein with a long-acting small molecule","volume":"584","author":"Link","year":"2020","journal-title":"Nature"},{"key":"2026090808571937300_dkag300-B19","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1016\/S2352-3018(22)00365-4","article-title":"Predicted effects of the introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling study","volume":"10","author":"Smith","year":"2023","journal-title":"Lancet HIV"},{"key":"2026090808571937300_dkag300-B20","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1038\/s41586-026-10154-x","article-title":"Integrase anchors viral RNA to the HIV-1 capsid interior","volume":"652","author":"Singer","year":"2026","journal-title":"Nature"},{"key":"2026090808571937300_dkag300-B21","doi-asserted-by":"publisher","first-page":"e1004882","DOI":"10.1371\/journal.pmed.1004882","article-title":"Optimising scale-up of injectable lenacapavir for HIV pre-exposure prophylaxis in South Africa: a modelling study and economic evaluation","volume":"23","author":"Jamieson","year":"2026","journal-title":"PLoS Med"},{"key":"2026090808571937300_dkag300-B22","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(26)00103-7","article-title":"Lenacapavir PrEP roll-out begins in Africa","volume":"13","author":"Adepoju","year":"2026","journal-title":"Lancet HIV"},{"key":"2026090808571937300_dkag300-B23","author":"Forbes Africa"},{"key":"2026090808571937300_dkag300-B24","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1056\/NEJMoa2115542","article-title":"Capsid inhibition with lenacapavir in multidrug-resistant HIV-1 infection","volume":"386","author":"Sorana","year":"2022","journal-title":"N Engl J Med"},{"key":"2026090808571937300_dkag300-B25","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1097\/COH.0000000000000713","article-title":"Lenacapavir: a first-in-class HIV-1 capsid inhibitor","volume":"17","author":"Dvory-Sobol","year":"2022","journal-title":"Curr Opin HIV AIDS"},{"key":"2026090808571937300_dkag300-B26","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1093\/jac\/dkaa060","article-title":"Frequency of capsid substitutions associated with GS-6207 in vitro resistance in HIV-1 from antiretroviral-naive and -experienced patients","volume":"75","author":"Marcelin","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2026090808571937300_dkag300-B27","author":"WHO"},{"key":"2026090808571937300_dkag300-B28","author":"UNAIDS"},{"key":"2026090808571937300_dkag300-B29","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1056\/NEJMoa0800971","article-title":"Early antiretroviral therapy and mortality among HIV-infected infants","volume":"359","author":"Violari","year":"2008","journal-title":"N Engl J Med"},{"key":"2026090808571937300_dkag300-B30","doi-asserted-by":"publisher","first-page":"e623","DOI":"10.1016\/S2352-3018(19)30193-6","article-title":"Prioritising the most needed paediatric antiretroviral formulations: the PADO4 list","volume":"6","author":"Penazzato","year":"2019","journal-title":"Lancet HIV"},{"key":"2026090808571937300_dkag300-B31","doi-asserted-by":"publisher","first-page":"783","DOI":"10.5863\/1551-6776-26.8.783","article-title":"Antiretroviral therapy in children and adolescents: a look into modern single tablet regimens","volume":"26","author":"Lee","year":"2021","journal-title":"J Pediatr Pharmacol Ther"},{"key":"2026090808571937300_dkag300-B32","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1097\/QAD.0000000000003835","article-title":"HIV viral suppression in children and adolescents 2\u2005years after transition to dolutegravir: a multicentre cohort study","volume":"38","author":"Khooa","year":"2024","journal-title":"AIDS"},{"key":"2026090808571937300_dkag300-B33","doi-asserted-by":"publisher","DOI":"10.7448\/IAS.18.1.20090","article-title":"Paediatric HIV treatment failure: a silent epidemic","volume":"18","author":"Bernheimer","year":"2015","journal-title":"J Int AIDS Soc"},{"key":"2026090808571937300_dkag300-B34","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1093\/nar\/gkg100","article-title":"Human immunodeficiency virus reverse transcriptase and protease sequence database","volume":"31","author":"Rhee","year":"2003","journal-title":"Nucleic Acids Res"},{"key":"2026090808571937300_dkag300-B35","first-page":"457","article-title":"2025 update of the drug resistance mutations in HIV-1","volume":"33","author":"Wensing","year":"2025","journal-title":"Top Antivir Med"},{"key":"2026090808571937300_dkag300-B36","doi-asserted-by":"publisher","first-page":"33","DOI":"10.12688\/f1000research.29032.1","article-title":"Sustainable data analysis with Snakemake","volume":"10","author":"M\u00f6lder","year":"2021","journal-title":"F1000Res"},{"key":"2026090808571937300_dkag300-B37","doi-asserted-by":"publisher","first-page":"i884","DOI":"10.1093\/bioinformatics\/bty560","article-title":"fastp: an ultra-fast all-in-one FASTQ preprocessor","volume":"34","author":"Chen","year":"2018","journal-title":"Bioinformatics"},{"key":"2026090808571937300_dkag300-B38","doi-asserted-by":"publisher","first-page":"3094","DOI":"10.1093\/bioinformatics\/bty191","article-title":"Minimap2: pairwise alignment for nucleotide sequences","volume":"34","author":"Li","year":"2018","journal-title":"Bioinformatics"},{"key":"2026090808571937300_dkag300-B39","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13059-018-1618-7","article-title":"An amplicon-based sequencing framework for accurately measuring intrahost virus diversity using PrimalSeq and iVar","volume":"20","author":"Grubaugh","year":"2019","journal-title":"Genome Biol"},{"key":"2026090808571937300_dkag300-B40","doi-asserted-by":"publisher","first-page":"3047","DOI":"10.1093\/bioinformatics\/btw354","article-title":"MultiQC: summarize analysis results for multiple tools and samples in a single report","volume":"32","author":"Ewels","year":"2016","journal-title":"Bioinformatics"},{"key":"2026090808571937300_dkag300-B41","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1093\/bioinformatics\/16.4.400","article-title":"Detecting hypermutations in viral sequences with an emphasis on G \u2192 A hypermutation","volume":"16","author":"Rose","year":"2000","journal-title":"Bioinformatics"},{"key":"2026090808571937300_dkag300-B42","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1128\/jvi.79.3.1975-1980.2005","article-title":"G\u2192A hypermutation in protease and reverse transcriptase regions of human immunodeficiency virus type 1 residing in resting CD4+ T cells in vivo","volume":"79","author":"Kieffer","year":"2005","journal-title":"J Virol"},{"key":"2026090808571937300_dkag300-B43","doi-asserted-by":"publisher","first-page":"e144","DOI":"10.1093\/nar\/gku739","article-title":"COMET: adaptive context-based modeling for ultrafast HIV-1 subtype identification","volume":"42","author":"Struck","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"2026090808571937300_dkag300-B44","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1093\/molbev\/mst010","article-title":"MAFFT multiple sequence alignment software version 7: improvements in performance and usability","volume":"30","author":"Katoh","year":"2013","journal-title":"Mol Biol Evol"},{"key":"2026090808571937300_dkag300-B45","doi-asserted-by":"publisher","DOI":"10.1093\/molbev\/msag061","article-title":"Piqtree: a python package for seamless phylogenetic inference with IQ-TREE","volume":"43","author":"McArthur","year":"2026","journal-title":"Mol Biol Evol"},{"key":"2026090808571937300_dkag300-B46","volume-title":"R: A Language and Environment for Statistical Computing","author":"R Core Team"},{"key":"2026090808571937300_dkag300-B47","doi-asserted-by":"publisher","first-page":"e0018725","DOI":"10.1128\/mbio.00187-25","article-title":"Impact of HIV-1 capsid polymorphisms on viral infectivity and susceptibility to lenacapavir","volume":"16","author":"Hansen","year":"2025","journal-title":"mBio"},{"key":"2026090808571937300_dkag300-B48","doi-asserted-by":"publisher","first-page":"42685","DOI":"10.1021\/jacs.5c13735","article-title":"Distinct target site of lenacapavir in immature HIV-1 and concurrent binding with the maturation inhibitor bevirimat","volume":"147","author":"Wu","year":"2025","journal-title":"J Am Chem Soc"},{"key":"2026090808571937300_dkag300-B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103584","article-title":"Association between transitioning to a dolutegravir-based regimen and risk of incident hypertension in adults with HIV in West Africa: a multicentre target trial emulation study","volume":"90","author":"Millot","year":"2025","journal-title":"EClinicalMedicine"},{"key":"2026090808571937300_dkag300-B50","doi-asserted-by":"publisher","DOI":"10.3389\/fviro.2023.1253661","article-title":"Dolutegravir resistance in sub-Saharan Africa: should resource-limited settings be concerned for future treatment?","volume":"3","author":"Kamori","year":"2023","journal-title":"Front Virol"},{"key":"2026090808571937300_dkag300-B51","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2025.1667417","article-title":"The warning bell of Dolutegravir resistance: rethinking HIV service models in Africa","volume":"13","author":"Ciccacci","year":"2025","journal-title":"Front Public Health"},{"key":"2026090808571937300_dkag300-B52","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1093\/cid\/ciae423","article-title":"Efficacy and safety of long-acting subcutaneous lenacapavir in heavily treatment-experienced people with multidrug-resistant HIV-1: week 104 results of a phase 2\/3 trial","volume":"80","author":"Ogbuagu","year":"2025","journal-title":"Clin Infect Dis"},{"key":"2026090808571937300_dkag300-B53","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1093\/infdis\/jiac364","article-title":"Resistance analyses in highly treatment-experienced people with human immunodeficiency virus (HIV) treated with the novel capsid hiv inhibitor Lenacapavir","volume":"226","author":"Margot","year":"2022","journal-title":"J Infect Dis"},{"key":"2026090808571937300_dkag300-B54","doi-asserted-by":"publisher","first-page":"e497","DOI":"10.1016\/S2352-3018(23)00113-3","article-title":"Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2\/3 trial","volume":"10","author":"Ogbuagu","year":"2023","journal-title":"Lancet HIV"},{"key":"2026090808571937300_dkag300-B55","doi-asserted-by":"publisher","first-page":"3644","DOI":"10.1038\/s41467-024-47254-z","article-title":"HIV transmission dynamics and population-wide drug resistance in rural South Africa","volume":"15","author":"Kemp","year":"2024","journal-title":"Nat Commun"},{"key":"2026090808571937300_dkag300-B56","doi-asserted-by":"publisher","first-page":"e0000826","DOI":"10.1371\/journal.pgph.0000826","article-title":"HIV-1 integrase resistance associated mutations and the use of dolutegravir in Sub-Saharan Africa: a systematic review and meta-analysis","volume":"2","author":"Ngoufack Jagni Semengue","year":"2022","journal-title":"PLOS Glob Public Health"},{"key":"2026090808571937300_dkag300-B57","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/S1473-3099(11)70149-9","article-title":"HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study","volume":"11","author":"Hamers","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"2026090808571937300_dkag300-B58","doi-asserted-by":"publisher","first-page":"e2311","DOI":"10.1093\/cid\/ciaa1161","article-title":"Pretreatment and acquired antiretroviral drug resistance among persons living with HIV in four African countries","volume":"73","author":"Crowell","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2026090808571937300_dkag300-B59","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s12977-018-0440-3","article-title":"Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir","volume":"15","author":"Oliveira","year":"2018","journal-title":"Retrovirology"},{"key":"2026090808571937300_dkag300-B60","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1093\/jac\/dkaf018","article-title":"Subtypes A1 and D, and recombinant HIV-1 natural polymorphisms associated with lenacapavir drug resistance in Uganda","volume":"80","author":"Omoding","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"2026090808571937300_dkag300-B61","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1126\/science.abb4808","article-title":"Structural and mechanistic bases for a potent HIV-1 capsid inhibitor","volume":"370","author":"Bester","year":"2020","journal-title":"Science"},{"key":"2026090808571937300_dkag300-B62","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1093\/jac\/dku426","article-title":"Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case\u2013control study using centralized ultrasensitive 454 pyrosequencing","volume":"70","author":"Cozzi-Lepri","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2026090808571937300_dkag300-B63","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1086\/650543","article-title":"Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure","volume":"201","author":"Paredes","year":"2010","journal-title":"J Infect Dis"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/10\/dkag300\/70993888\/dkag300.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/10\/dkag300\/70993888\/dkag300.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:57:34Z","timestamp":1788872254000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/doi\/10.1093\/jac\/dkag300\/8787873"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":63,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkag300","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,9,1]]},"article-number":"dkag300"}}